Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
Main Authors: | Anna May Suidan, Laila Roisman, Anna Belilovski Rozenblum, Maya Ilouze, Elizabeth Dudnik, Alona Zer, Nir Peled |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society of Clinical Oncology
2019-05-01
|
Series: | Journal of Global Oncology |
Online Access: | http://ascopubs.org/doi/10.1200/JGO.18.00216 |
Similar Items
-
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
by: Elizabeth Dudnik, et al.
Published: (2021-03-01) -
Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
by: Michal Sternschuss, et al.
Published: (2020-08-01) -
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
by: Anna-Leigh Brown, et al.
Published: (2019-04-01) -
Long term follow-up of EGFR mutated NSCLC cases
by: Gad Rennert, et al.
Published: (2021-01-01) -
Homeownership Rates, the Higher, the Better?
by: Lien Hsin-Chang, et al.
Published: (2009)